Business Description
Ensysce Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US2936025046
Share Class Description:
ENSC: Ordinary SharesTotal Employee Number:
10Description
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.03 | |||||
Equity-to-Asset | -0.16 | |||||
Debt-to-Equity | -0.72 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 87.4 | |||||
3-Year EPS without NRI Growth Rate | 87.6 | |||||
3-Year FCF Growth Rate | 87.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.46 | |||||
9-Day RSI | 44.36 | |||||
14-Day RSI | 44.55 | |||||
3-1 Month Momentum % | -48.89 | |||||
6-1 Month Momentum % | -76.13 | |||||
12-1 Month Momentum % | -88.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -402.8 | |||||
Shareholder Yield % | 0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -560.44 | |||||
ROA % | -256.38 | |||||
ROIC % | -1699.11 | |||||
3-Year ROIIC % | -320.44 | |||||
ROC (Joel Greenblatt) % | -9645.9 | |||||
ROCE % | -653.71 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.07 | |||||
EV-to-EBIT | -0.29 | |||||
EV-to-EBITDA | -0.29 | |||||
EV-to-Forward-Revenue | 0.55 | |||||
EV-to-FCF | -0.35 | |||||
Earnings Yield (Greenblatt) % | -344.83 | |||||
FCF Yield % | -227.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENSC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ensysce Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.35 | ||
| Beta | 0.1167 | ||
| 3-Year Sharpe Ratio | -0.85 | ||
| 3-Year Sortino Ratio | -1.3 | ||
| Volatility % | 56.59 | ||
| 14-Day RSI | 44.55 | ||
| 14-Day ATR ($) | 0.025947 | ||
| 20-Day SMA ($) | 0.277095 | ||
| 12-1 Month Momentum % | -88.45 | ||
| 52-Week Range ($) | 0.23 - 2.75 | ||
| Shares Outstanding (Mil) | 15.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ensysce Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ensysce Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-23 09:00 | In 168 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 127 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 35 days | ||
| First quarter earnings results for 2026 | 2026-05-15 | 0.28 (+2.67%) | ||
| First-ever European Pain Therapeutics Summit | 2026-05-07 | 0.39 (-3.68%) | ||
| Annual report for 2025 | 2026-03-30 | 0.53 (-1.60%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 0.53 (-1.60%) | ||
| General meeting for 2025 | 2025-12-23 09:00 | 1.18 (+1.72%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 2.07 (+0.38%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 2.09 (+3.98%) |
Show
Entries
Ensysce Biosciences Inc Frequently Asked Questions
What is Ensysce Biosciences Inc(ENSC)'s stock price today?
The current price of ENSC is $0.28. The 52 week high of ENSC is $2.75 and 52 week low is $0.23.
When is next earnings date of Ensysce Biosciences Inc(ENSC)?
The next earnings date of Ensysce Biosciences Inc(ENSC) is 2026-08-13 Est..
Does Ensysce Biosciences Inc(ENSC) pay dividends? If so, how much?
Ensysce Biosciences Inc(ENSC) does not pay dividend.
Guru Commentaries on NAS:ENSC
No articles.
Press Release
Articles on Ensysce Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers